Business Daily Media

Business Marketing

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

  • Written by ACN Newswire - Press Releases

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

TOKYO, Jun 24, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD).Breakthrough Therapy

Read more //?#

Popular

These celebrity-owned brands are the most profitable

The study revealed that Yeezy by Kanye West is the celebrity brand with the highest revenues, making 1.7 billion a year.  The study from Hey Discount analysed a number of celebrity-owned brands based on factors such as reve...

Brisbane’s healthcare market set to expand with a new holistic pharmacy brand

Brisbane will soon be home to two innovative new healthcare destinations with the launch of new holistic pharmacy brand Wholehealth Pharmacy and Healthfoods, which is set to shake up the local health market in Toowong and West E...

5 Work From Home Ideas to Start Today

Working from home used to be only for a privileged few and most people had to commute long distances to report to work. But advances in information technology have made it easy for most people to work from home. You might b...

Virtual Office
Tomorrow Business Growth